Neoepitope Detection of Cancer using Protein Arrays
<- Return to Search Page
- Categories
- Biotechnology, Diagnostics
- Summary
- This technology is a new diagnostic chip technology with the express aim of developing new commercial products for the early detection of ovarian cancer and other diseases. The technology employs pattern recognition as a diagnostic rather than a single marker using specialized informatics techniques to interpret the results on numerous markers using biochip technology and specialized laser scanning instrumentation.
The diagnostic epitope markers are identified by exploiting the immune system’s reaction to a tumor as a foreign entity. The epitope markers are spotted on a microarray and then exposed to the patient’s diluted serum. This new technology can quantitatively identify the presence of cancer-specific antibodies by measuring the fluorescence of a labeled anti-human antibody recognizing the patient’s own antibodies bound to the epitope clones. The advantages of this microarray biochip technology are its greater sensitivity, its quantitative capacity and small serum requirement.
- File number
- 01-544 & 04-699
- Publications
- A U.S. patent application is on file. A set of ovarian cancer markers are available; U.S. protection is pending for the markers.
- Contact
- Anne DiSante
Director, Technology Transfer Office
Phone: 313-577-5541
Fax : 313-577-2814
anne.disante@wayne.edu